The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Efficacy and safety of continued zoledronic acid every 4 weeks versus every 12 weeks in women with bone metastases from breast cancer: Results of the OPTIMIZE-2 trial.
Gabriel N. Hortobagyi
Consultant or Advisory Role - Novartis
Research Funding - Novartis
Allan Lipton
Honoraria - Novartis
Research Funding - Novartis
Expert Testimony - Novartis
Helen K. Chew
No relevant relationships to disclose
William John Gradishar
No relevant relationships to disclose
Nicholas P. Sauter
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Ramon W. Mohanlal
Employment or Leadership Position - Novartis
Ming Zheng
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Beth McGrain
Employment or Leadership Position - Novartis
Catherine Van Poznak
Consultant or Advisory Role - Novartis
Research Funding - Novartis